Investment Strategist Recommends Buying Baxter Over Eli Lilly Amidst GLP-1 Craze

Great Hill Capital Chairman and Managing Member Tom Hayes suggests buying Baxter International (BAX) as a play on the GLP-1 hype, citing its aggressive sell-off, tremendous valuation, and potential catalysts for stock recovery. On the other hand, Hayes advises against buying Eli Lilly (LLY), stating that the stock has already priced in positive news, faces increased competition, and uncertainty regarding insurance coverage for obesity drugs.